The 2023-2028 Outlook for Precision Medicines for US Zip Codes

January 2023 | 512 pages | ID: 2B20A109E3BDEN
ICON Group International

Abstracts

This study covers the latent demand outlook for precision medicines across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for precision medicines. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of precision medicines as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include 23andMe, Ab-Biotics Sa, Abbott, Abcodia, ACS Biomarker, Actelion Pharmaceuticals, Advanced Biological Laboratories, Advaxis, Affymetrix, Agendia, Agenus, Alacer Corporation, Alberta Cancer Research Biobank, Alios BioPharma, Inc., Almac, Amgen, Apple, Archimedes, Aspen, Astellas Pharma, AstraZeneca, Astute Medical, Asuragen, AT&T, Athenahealth, Aurora, Auspex Pharmaceuticals, Avon Longitudinal Study of Parents and Children, Bayer, BGI Tech Solutions Company, Ltd., Biocrates Life Sciences, BioFortis, BioGene, Biomerieux, bioM?rieux, BioNTech, Bioven International Sdn Bhd, Bode Technology group, Inc., Bristol-Myers Squibb, CareWell Urgent Care, Caris, Celera Diagnostics, Cell & Co Biorepository, Celtics Healthcare, Cepheid, Cetics Healthcare Technologies Gmbh, CFR Pharmaceuticals, Ciba-Geigy, Clarient Diagnostic Services, Inc., Cognizant, Cooperative Human Tissue Network, Copan, Covance, Cubist Pharmaceuticals, CureVac, Daiichi Sankyo Company, Dako, Dell, Diabeter, Eagle Genomics, Ltd., Eli Lilly, Estonian Genome Project, F. Hoffmann-La Roche, Ferrer InCode, Ferring Pharmaceuticals, Fisher BioServices, Flakka, Foundation Medicine, GE Healthcare, Genome Medicine, Genomic Health, GenoSpace, Gen-Probe, GlaxoSmithKline, Glooko, Google, Gritstone Oncology, Hologic, Human Tissue Resource Network, HUNT Biobank, IBM, Idera Pharmaceuticals, Illumina, Immatics Biotechnologies, Immuneering Corporation, Immunovative Therapies, Infectio Diagnostic, Inc., Institutional Biobank of Lausanne, Intel, Intomics, Janssen Biotech, Japan Post Group, Johnson & Johnson, Kaiser Permanente, Lab-Ally, Laboratory Corporation of America, LG, Life Technologies, llumina, Luminex Molecular Diagnostics, Inc., Lutron Electronics, Mayo Clinic, Medpace, Medtronic, Merck, Moderna, Modul-Bio, Molecular Health, Monogram Bioscience, Myriad Genetic Laboratories, Nanosphere, NanoString, NantKwest, Neon Therapeutics, NextWave, Novartis, Omnyx, LLC, OncoMed Pharmaceuticals, Oncotype DX, OneMedNet Corporation, Oracle Healthcare, Panasonic Healthcare, PATH Biobank, Personalis, Pfizer, Philips Healthcare, ProMedDx, Q2 Solutions, Qiagen, Qualcomm, Quest Diagnostics, Randox Laboratories, Reddy Laboratories, Roche, Royal Philips, Samsung, Sandoz, Sanofi Aventis, Siemens Clinical Lab, Signature Diagnostics AG, St. Jude Medical (SJM), Sterand, PLC, Syapse, Sysmex, Takeda Pharmaceutical Company, Tepnel Pharma Services, Teva Pharmaceutical Industries, Therascreen, Thermo Fisher Scientific, Topera, Trofile, U.K. Biobank, UMass Cancer Center Tissue and Tumor Bank, Ventana Medical Systems, Veropharm, Vysis, and Zinfandel Pharmaceuticals. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Contents

1 INTRODUCTION

1.1 OVERVIEW
1.2 WHAT IS LATENT DEMAND AND THE P.I.E.?
1.3 THE METHODOLOGY
  1.3.1 STEP 1. PRODUCT DEFINITION AND DATA COLLECTION
  1.3.2 STEP 2. FILTERING AND SMOOTHING
  1.3.3 STEP 3. FILLING IN MISSING VALUES
  1.3.4 STEP 4. VARYING PARAMETER, NON-LINEAR ESTIMATION
  1.3.5 STEP 5. FIXED-PARAMETER LINEAR ESTIMATION
  1.3.6 STEP 6. AGGREGATION AND BENCHMARKING
1.4 FREQUENTLY ASKED QUESTIONS (FAQ)
  1.4.1 CATEGORY DEFINITION
  1.4.2 UNITS
  1.4.3 METHODOLOGY

2 SUMMARY OF FINDINGS

2.1 LATENT DEMAND IN THE UNITED STATES
2.2 LATENT DEMAND BY YEAR IN THE UNITED STATES
2.3 TOP 100 CITIES IN THE UNITED STATES

3 FAR WEST

3.1 EXECUTIVE SUMMARY
3.2 LATENT DEMAND BY YEAR - ALASKA
3.3 CITIES SORTED BY ZIPCODE - ALASKA
3.4 LATENT DEMAND BY YEAR - CALIFORNIA
3.5 CITIES SORTED BY ZIPCODE - CALIFORNIA
3.6 LATENT DEMAND BY YEAR - HAWAII
3.7 CITIES SORTED BY ZIPCODE - HAWAII
3.8 LATENT DEMAND BY YEAR - NEVADA
3.9 CITIES SORTED BY ZIPCODE - NEVADA
3.10 LATENT DEMAND BY YEAR - OREGON
3.11 CITIES SORTED BY ZIPCODE - OREGON
3.12 LATENT DEMAND BY YEAR - WASHINGTON
3.13 CITIES SORTED BY ZIPCODE - WASHINGTON

4 GREAT LAKES

4.1 EXECUTIVE SUMMARY
4.2 LATENT DEMAND BY YEAR - ILLINOIS
4.3 CITIES SORTED BY ZIPCODE - ILLINOIS
4.4 LATENT DEMAND BY YEAR - INDIANA
4.5 CITIES SORTED BY ZIPCODE - INDIANA
4.6 LATENT DEMAND BY YEAR - MICHIGAN
4.7 CITIES SORTED BY ZIPCODE - MICHIGAN
4.8 LATENT DEMAND BY YEAR - OHIO
4.9 CITIES SORTED BY ZIPCODE - OHIO
4.10 LATENT DEMAND BY YEAR - WISCONSIN
4.11 CITIES SORTED BY ZIPCODE - WISCONSIN

5 MID-ATLANTIC

5.1 EXECUTIVE SUMMARY
5.2 LATENT DEMAND BY YEAR - DELAWARE
5.3 CITIES SORTED BY ZIPCODE - DELAWARE
5.4 LATENT DEMAND BY YEAR - DISTRICT OF COLUMBIA
5.5 CITIES SORTED BY ZIPCODE - DISTRICT OF COLUMBIA
5.6 LATENT DEMAND BY YEAR - MARYLAND
5.7 CITIES SORTED BY ZIPCODE - MARYLAND
5.8 LATENT DEMAND BY YEAR - NEW JERSEY
5.9 CITIES SORTED BY ZIPCODE - NEW JERSEY
5.10 LATENT DEMAND BY YEAR - NEW YORK
5.11 CITIES SORTED BY ZIPCODE - NEW YORK
5.12 LATENT DEMAND BY YEAR - PENNSYLVANIA
5.13 CITIES SORTED BY ZIPCODE - PENNSYLVANIA

6 NEW ENGLAND

6.1 EXECUTIVE SUMMARY
6.2 LATENT DEMAND BY YEAR - CONNECTICUT
6.3 CITIES SORTED BY ZIPCODE - CONNECTICUT
6.4 LATENT DEMAND BY YEAR - MAINE
6.5 CITIES SORTED BY ZIPCODE - MAINE
6.6 LATENT DEMAND BY YEAR - MASSACHUSETTS
6.7 CITIES SORTED BY ZIPCODE - MASSACHUSETTS
6.8 LATENT DEMAND BY YEAR - NEW HAMPSHIRE
6.9 CITIES SORTED BY ZIPCODE - NEW HAMPSHIRE
6.10 LATENT DEMAND BY YEAR - RHODE ISLAND
6.11 CITIES SORTED BY ZIPCODE - RHODE ISLAND
6.12 LATENT DEMAND BY YEAR - VERMONT
6.13 CITIES SORTED BY ZIPCODE - VERMONT

7 PLAINS

7.1 EXECUTIVE SUMMARY
7.2 LATENT DEMAND BY YEAR - IOWA
7.3 CITIES SORTED BY ZIPCODE - IOWA
7.4 LATENT DEMAND BY YEAR - KANSAS
7.5 CITIES SORTED BY ZIPCODE - KANSAS
7.6 LATENT DEMAND BY YEAR - MINNESOTA
7.7 CITIES SORTED BY ZIPCODE - MINNESOTA
7.8 LATENT DEMAND BY YEAR - MISSOURI
7.9 CITIES SORTED BY ZIPCODE - MISSOURI
7.10 LATENT DEMAND BY YEAR - NEBRASKA
7.11 CITIES SORTED BY ZIPCODE - NEBRASKA
7.12 LATENT DEMAND BY YEAR - NORTH DAKOTA
7.13 CITIES SORTED BY ZIPCODE - NORTH DAKOTA
7.14 LATENT DEMAND BY YEAR - SOUTH DAKOTA
7.15 CITIES SORTED BY ZIPCODE - SOUTH DAKOTA

8 ROCKIES

8.1 EXECUTIVE SUMMARY
8.2 LATENT DEMAND BY YEAR - COLORADO
8.3 CITIES SORTED BY ZIPCODE - COLORADO
8.4 LATENT DEMAND BY YEAR - IDAHO
8.5 CITIES SORTED BY ZIPCODE - IDAHO
8.6 LATENT DEMAND BY YEAR - MONTANA
8.7 CITIES SORTED BY ZIPCODE - MONTANA
8.8 LATENT DEMAND BY YEAR - UTAH
8.9 CITIES SORTED BY ZIPCODE - UTAH
8.10 LATENT DEMAND BY YEAR - WYOMING
8.11 CITIES SORTED BY ZIPCODE - WYOMING

9 SOUTHEAST

9.1 EXECUTIVE SUMMARY
9.2 LATENT DEMAND BY YEAR - ALABAMA
9.3 CITIES SORTED BY ZIPCODE - ALABAMA
9.4 LATENT DEMAND BY YEAR - ARKANSAS
9.5 CITIES SORTED BY ZIPCODE - ARKANSAS
9.6 LATENT DEMAND BY YEAR - FLORIDA
9.7 CITIES SORTED BY ZIPCODE - FLORIDA
9.8 LATENT DEMAND BY YEAR - GEORGIA
9.9 CITIES SORTED BY ZIPCODE - GEORGIA
9.10 LATENT DEMAND BY YEAR - KENTUCKY
9.11 CITIES SORTED BY ZIPCODE - KENTUCKY
9.12 LATENT DEMAND BY YEAR - LOUISIANA
9.13 CITIES SORTED BY ZIPCODE - LOUISIANA
9.14 LATENT DEMAND BY YEAR - MISSISSIPPI
9.15 CITIES SORTED BY ZIPCODE - MISSISSIPPI
9.16 LATENT DEMAND BY YEAR - NORTH CAROLINA
9.17 CITIES SORTED BY ZIPCODE - NORTH CAROLINA
9.18 LATENT DEMAND BY YEAR - SOUTH CAROLINA
9.19 CITIES SORTED BY ZIPCODE - SOUTH CAROLINA
9.20 LATENT DEMAND BY YEAR - TENNESSEE
9.21 CITIES SORTED BY ZIPCODE - TENNESSEE
9.22 LATENT DEMAND BY YEAR - VIRGINIA
9.23 CITIES SORTED BY ZIPCODE - VIRGINIA
9.24 LATENT DEMAND BY YEAR - WEST VIRGINIA
9.25 CITIES SORTED BY ZIPCODE - WEST VIRGINIA

10 SOUTHWEST

10.1 EXECUTIVE SUMMARY
10.2 LATENT DEMAND BY YEAR - ARIZONA
10.3 CITIES SORTED BY ZIPCODE - ARIZONA
10.4 LATENT DEMAND BY YEAR - NEW MEXICO
10.5 CITIES SORTED BY ZIPCODE - NEW MEXICO
10.6 LATENT DEMAND BY YEAR - OKLAHOMA
10.7 CITIES SORTED BY ZIPCODE - OKLAHOMA
10.8 LATENT DEMAND BY YEAR - TEXAS
10.9 CITIES SORTED BY ZIPCODE - TEXAS

11 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS

11.1 DISCLAIMERS & SAFE HARBOR
11.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS